许瑞安教授
许瑞安教授
发布时间:　　浏览次数:
Name&&& Ruian ( Ray) Xu& (PhD& Otago)&&&&& 许瑞安
Mailing Address:
Professor and Director
Engineering Research Center of Molecular Medicine
Ministry of Education
518/519 Shengjun Building
Huaqiao University Main Campus
Fujian, CHINA 362021
国际癌细胞与基因疗法学会常务理事、国际口服基因疗法主要发明人之一、国家科技部科技发展战略专家/国际科技合作管理专家、国家教育部学位中心评审专家、国家教育部分子药物工程研究中心主任、福建省生物医药工程研究生培养基地负责人、福建省医学生物化学专业委员会主任、华侨大学生物医学学院/分子药物研究院院长、厦门市生物医学国际科技合作基地负责人、教授、博士生导师，美、英、德以及瑞典卡罗琳医学院Hepatology、Gene&Therapy等20余家SCI&学术刊物编委/审稿人、《药学学报》编委、北京协和医学院荣誉教授、“行政院”台北荣民总院荣誉教授、爱尔兰国家自然基金评审专家、新西兰食品科学技术研究院专业委员、中国海洋大学海洋药物客座教授，山东大学兼职教授。
1983&年录取国家教育部出国公派留学，1989年获得Otago&大学博士学位，在加拿大完成博士后，一直在国外多家著名国际大学、科研机构从事科研教学工作，先后出任过大学载体研究中心、神经载体研究室主任。其分子药学研究工作发表于Nature&Medicine[文章发表于1998年第5期封面]、Science、PNAS、Hepatology、Gastroentrology、Cancer&Research等国际学术刊物。从1983年起至今已发表SCI学术论文100余篇，影响因子&500分；并申报/获得专利发明26项。2005&年发表在美国《医学科学检测》&杂志的“Stability&of&Infectious&rAAV&vector&stock&”一文被世界卫生组织定为分子疗法临床应用的主要参考文献之一。先后主持中外重大专项20余项，并担任国家863“十五”肺癌基因疗法课题组组长、首席科学家、肝癌基因疗法课题组副组长、国家863“十一五”肺癌基因疗法课题组首席科学家。主编《分子基因药物学》110万字，北京大学出版社&&&北京大学医学出版社联合出版（被选为我国2008年最佳科技图书），《细胞工程与分子生物技术》化学工业出版社&70万字，《腺相关病毒—从病毒到临床应用》70万字，科学出版社&2014，上海；合编《Trends&in&Gene&Therapy&Research》NOVA&Science&Publisher，New&York，USA(2006)。
2007&年入选美国Marquis&科学工程版Who&is&who；2008年入选美国Marquis&国际版Who&is&who。
2009年入选泉州市人民政府首批“桐江学者”；2010年获中国侨界双百奖（创新人才奖）；福建省人民政府“国际友谊奖”；同年任第二届国际定量药理学与新药评价会议主席。2011年入选“科学中国人”2010年年度人物；2012年许瑞安团队入选福建省委省政府“百人计划”“许瑞安创新团队”；2014年“许瑞安团队”获得“中国侨界贡献奖”；同年个人入选厦门市双百人才（创业）奖；“许瑞安团队”入选华侨大学3大引领型创新团队。
主要研究兴趣：&
（1）分子医学、基因工程药物与基因治疗&（在研资金：国家863，&国家自然资金，&福建省“百人计划”，&华侨大学引领型创新团队）
（2）海洋药物与纳米功能食品&（在研资金：&国家海洋公益项目，&福建省“百人计划”，&厦门市“双百”计划，厦门市南方海洋研究中心，华侨大学引领型创新团队）
PATENT APPLICATIONS:(16)
Name of Inventors
Application Number
Title of Patent
&RA Xu, X., Ma
Transducting intestine cells by oral gene delivery&
&RA Xu， Y., Diao，K., Cai
Vasostatin for inhibiting lung cancer metstasis&
&RA Xu; G.,Wang, Y. Diao
Production and application of recombinant cytoglobin&
&D Z RA Xu, H Ma, Y Liu, X Kung
A recombinant soluble tumor necrosis factor-related apoptosis-inducing ligand sequence and application&
&RA Xu, X Sun, ST Fang, X Kung, G&Kressen
Synergizing with angiostatin adeno-associated virus-mediated B7.1 vaccination to eradicate the spread of metastatic tumor
&RA Xu, X L, P Fung
A drug for prevention and treatment of liver cirrhosis&
&RA Xu, L Tse, Y Diao
Two kinds of novel angiogenesis inhibitor drugs and their application to Combat Cancer&
&RA Xu, P Fung, J Zhu
Methodology and application of A anti-colon cancer gene mediecine&
&Y D RA Xu
Of an anti-cardiovascular and cerebrovascular diseases, traditional Chinese medicine composition and its preparation method&
&Q Z RA Xu
A Method for preparation of ethyl cinnamate derivatives&
&RA Xu, W Xiao, H Lu
A new type of cell-specific microRNA binding gene sequence containing HAAVmir for gene therapy&
&黄晓平;李招发;刁勇;许瑞安
一种分泌表达人Kallistatin的重组酵母菌株及生产工艺&
&许瑞安，张亭亭、李招发、刁勇
重组细胞球蛋白在延缓皮肤衰老中的应用&
许瑞安，吴龙火&
一种 (&)-Murracarpin的合成方法及其抗炎作用&
许瑞安，施伟杰&
融合Tat人源细胞球蛋白及其在治疗肝癌中的应用&
&许瑞安、王晓
&鳄鱼鳞的提取及其临床应用
PUBLICATIONS
I. Total Chapters of Books: 15
1. 1 Chapter Xu RA* et al. Oral viral gene delivery （33pages）, In: Trends in Gene Therapy Research （2006） NOVA SCIENCE，Publisher, New York, USA （An invitation to Xu RA from NOVA& Science Publisher, New York, USA）
2. 9 Chapters In: Molecular Gene Medicine。Xu RA*, Chen L, Xiao WD
(Es), Peking University Press & Peking University& Medical Press, 2008.2
《分子基因药物学》 许瑞安*、陈凌、肖卫东主编& 110万字 北京大学出版社 & 北京大学医学出版社联合出版， 2008年， 北京。
①& Chapter 3 Molecule drug delivery channels and intestinal absorption of nano-particles&&&& RA Xu*&&&& pp68-90
②& Chapter 4&& Aptamer Molecular Pharmacology&&& J Lin、RA Xu&& pp 91-104
②& Chapter 7&& Molecular therapy of Parkinson's disease and Prospects&& Jia L, RA Xu&& pp 175-205
④& Chapter 8&& Molecular therapy of hepatitis B&&&& Li H、RA Xu*&&& pp 206-245
⑤& Chapter 10& Molecular treatment of the liver cirrhosis&&&& Li,X, Y Lv, RA Xu* pp 272-301
⑥& Chapter 13& Diabetes gene drug R & D&&& Liu Q., Cai S, RA Xu*&& pp 346-390
⑦& Chapter 14& Cranial mandibular defect repair of modern medicine&& Diao Y., RA Xu*&&& pp 391-432
⑧& Chapter 15& Molecular pathogenesis and therapy of lung cancer&& Wang Q, Y Diao, RA Xu*&& pp 433-525
⑨& Chapter 16& New treatment for liver cancer&&&&&&&&& Sun, X., RA Xu*&&& pp 525-565
⑩& Chapter 17& Molecular therapy of colon cancer&&&& Lv Y., Wang Q., RA Xu*&&& pp 566-627
⑾& Chapter 18& Stem cells and cancer stem cells&&&& Wang Q, Y Lv, RA Xu*&& pp 628-678
3. 5 Chapters In: Cell Engineering and Biotechnology&& Diao Y, Xu RA (Es)
Chemical Industry Press, Peking, 2008
《细胞工程与生物技术实验指南》 刁勇 许瑞安*主编& 70万字 化学工业出版社
2008 年， 北京。
①&&& Chapter 1 Infrastructure of Cells and biotechnology& X&&& Wang X, W Shi, RA Xu& pp 1-9
②&&& Chapter 6& Induction of cell differentiation technology&&& W Tang, RA Xu*&&&& pp 167-197
③&&& Chapter 9 Mammalian cells RNAi&&&& Q Wang、RA Xu*& pp221-258
③&&& Chapter 13 Cells and recombinant virus vector technology&& F. Wang, RA Xu*&&& pp306-337
⑤&&& Chapter 16 Application of Cellular Biotechnology&&&&& Liu J, Y Diao, RA Xu* pp379-415
4. 1 chapter& In:
Chapter 6& Biologics R & D and pharmacodynamic evaluation of route of administration of drugs--- Gene drug route of administration and efficacy evaluation of Efficacy&&&& RA Xu* H Luo
2. Total Peer Review Articles ( & 100 )
List of Recent 12-year Peer Review Articles
1& Zhang G, Wang Q, Xu RA*&& Therapeutics Based on microRNA: An New Approach for Liver Cancer. Current Genomics, 11(5), 311-325, 2010 PubMed ID (20) DOI: 10.
2& Lu H, Qu, G, Ding Q, Wang X, Xu RA, Xiao W&&&& A new type of cell-specific microRNA binding gene sequence containing HAAVmir for gene therapy&& Human Gene Therapy& (2011) PubMed ID:()
3& Lijuan Xie, Jingnan Cui, Xuhong Qian, Yufang Xu, Jianwen Liu, R.A.Xu. 5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior. Bioorganic & Medicinal Chemistry ): 961-967.
4& Diao Yong, Zhao Xiaofeng, Lin Junsheng, Wang Qizhao, R.A.Xu*. Protection of the liver against CCl4-induced injury by intramuscular electrotransfer of a kallistatin-encoding plasmid World J Gastroenterol 2011 J 17(1): 111-117.
5& Wu Longhuo, Li Pei, Wang Xiao, Zhuang Zhenjing, Farzaneh Farzin, R.A.Xu*. Evaluation of anti-inflammatory and antinociceptive activities of Murraya exotica. Pharmaceutical biology ):1344-53. PubMed ID ()
6& William Xu, Qi Zhao Wang, Qi Cui, R.A.Xu**. MicroRNA polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility. Current Pharmacogenomics and Personalized Medicine. 2010 D 8(4): 289-305(17).
7& Tang Mq Tang M, Xu W, Wang Q, Xu RA*. DNMT and its related epigenetic regulation in lung tumorigenesis. Current Genomics, ):336-52&&& PubMed ID () SCI
8& Wu L, Wang X, Xu W, Farzaneh F, Xu RA*.& The Structure and pharmacoligical functions of coumarin and their deveritives& Current Medicinal Chemistry ): 4236-60. PubMed ID ()
9& Sun X, Jiang H, Jiang X, Tan H, Meng Q, Sun B, Xu RA, Krissansen GW Antisense hypoxia-inducible factor-1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats. Hum Gene Ther. ):314-24. PubMed ID ().
10& Wang Q, Xu W, Habib N, Xu RA*. Potential uses of microRNA in lung cancer diagnosis, prognosis and therapy. Current Cancer Drug Targets, ）:572-594 PubMed ID ()
11& Jiang X, Li H, Qiao H, Jiang H, Xu R, Sun X& Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. ):2226-33. PubMed ID ().
12& Lv Y, Wang Q, Diao Y, Xu RA*.& Cytoglobin: Novel Potential Gene Medicine for Fibrosis and Cancer Therapy. Current Gene Therapy, 7-294 PubMed ID: ( )
13& Lv Y, Wang Q, Xiao W, Diao Y, Xu RA* Trends in development of self-complementary adeno-associated virus vector Sheng wu gong cheng xue bao = Chinese journal of biotechnology ):658~66 PubMed ID: ( )
14& Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu R, Sun X& Down-regulating hypoxia-inducible factor 1 alpha augments transcatheter arterial embolization to treat hepatocellular carcinomas in rats. Human Gene Therapy (2008) (Epub 22 Dec 2008), PubMed ID:()
15& Diao Y, Ma J, Li X, Sun X, Xu R. Construction and activity of recombinant adeno-associated virus expressing vasostatin. Sheng wu gong cheng xue bao = Chinese journal of biotechnology 24 (11) , 08) PubMed ID:()
16& Wang Q, Lv Y, Xu RA*. The design of vectors for RNAi delivery system. Curr Pharm Design ）：. (An invitation from Editor-in-chief to Xu RA) PubMed ID:()
17& Lu H, Chen L, Wang J, Huack B, Sarkar R, Zhou S, Xu R, Ding Q, Wang X, Wang H, Xiao W. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Human Gene Therapy 19 (6) , 648-54 (2008) PubMed ID:()
18& Tse LY，Sun X*, Jiang H, Dong X, Fung PWC, Farzaneh F, Xu R*. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular varcinomas. J Gene Med ) , 508-17& PubMed ID:()?
19& Li H, Li XY, Lam, KS, Cheung T, Xu RA* Adeno-associated virus-mediated pancreatic and duodenalmhomeobox gene-1 expression enhanced differentiation of hepatic oval stem cells to insulin-producing cells in diabetic rats. J Med Sci, -497& PubMed ID:( )
20& Cai, K, Tam P, Xu RA, Shan MH. Suppression of lung tumor metastasis in mice by recombinant adeno-associated virus-mediated expression of vasostatin Clin Cancer Res ) , 939-49 PubMed ID:( )
21&&& Rabie AB, Dai J, Xu RA. Recombinant adeno-associated virus mediated vascular endothelial growth factor gene therapy induces mandibular condylar growth. Gene Ther 2–980 PubMed ID:( )
22& Jiang H, Meng Q, Tan H, Pan S, Sun B, Xu RA, Sun X. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer ):416-24 PubMed ID:()
23& Wang D, Liu W, Han B, Xu R. Biochemical and enzymatic properties of a novel marine fibrinolytic enzyme from Urechis unicinctus. Appl Biochem Biotech ):251-64. PubMed ID:( )
24& Xu RA, Harrison, PM, Chen, M,Li, XY, Tsui T-Y, Fung PCW, Cheung P-T, Guangji Wang G, Li H, Diao Y, Xu S, Krissansen GW, Farzaneh F. Cytoglobin protects against damage-induced liver fibrosis. Mol Ther ): PubMed ID:( )
25& Xu RA, Zhao B, Fung P, Li XY. Histology and histopathology 7-92 (An invitation from Editor-in-chief, Professor Hernz-calvo to Xu RA) PubMed ID:( )
26& Bernd H, Xu RA, Xie J, Ding Q, Sipler M, Wang H, Chen, L, Xiao WD. An efficient AAV1/AAV2 hybrid vector for gene therapy of Hemophilia. Human Gene Therapy ):46-54. PubMed ID:()
27& Ma H, Liu Y, Liu S, Xu RA*, Zheng D*. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology ):1355-63. PubMed ID:( )
28&& Shi J, Liu Y, Guo J, Zhang D, Zheng D,& Li X, Cheung P-t, Farzaneh F, Xu RA*.　Expression of an anti-DR5 single chain antibody in muscles of nude mice prevents lung cancer growth. Cancer Res ):11946-53. PubMed ID:()
29&& Lee TK, Man K, Ho JW, Wang HX, Poon RT, Sun KW, Ng KT, Ng IO, Xu RA, Fan ST. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res ):8458-66. PubMed ID:()
30&& Tsui TY, Lau CK, Wu X, Wang YQ, Siu YT, Xu RA, Schlitt HJ, Fan ST Hemo oxygnase-1 gene therapy attenuates micronodular Liver cirrhosis in rat. Hepatology ):335-42. PubMed ID:( )
31& Ma H, Zheng D*, Liu Y, Liu S, Kung HF, Sun X, Xu RA*. AAV-Mediated TRAIL gene therapy suppresses liver metastatic tumors. International Journal of Cancer ):314-21. PubMed ID:( )
32& Chen M, Wang GJ, Diao Y, Xie H, Li X, Sun J, Xu RA. AAV-mediated interferon-gamma ameliorates the hepatic fibrosis in vitro and in vivo. World J Gastroenterology ):4045-51. PubMed ID:()
33& Wang DL, Hu Q, Xu RA*. The bioreactor: a powerful tool for large-scale preparation for animal cells. Curr Pharm Biotech ):397-403.
34& Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu RA*. Over-expression of soluble tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 7-92. PubMed ID:()
35& Sun X, Qiao H, Jiang H, Zhi X, Liu F, Wang J, Liu M, Dong D, Kanwar JR, Xu RA, Krissansen GW. Intramuscular delivery of anti-angiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Ther ) 35-45. PubMed ID:()
36& Xu RA*, Ma H, Fung PCW, Chang Q, Xu S, During MJ Stability of infectious recombinant AAV vector. Medical Science Monitor ) BR305-308 PubMed ID:()
37& Dai J, Rabie AB, Hagg, EUO, Xu RA*. A novel strategy for repair of craniofacial bone defects. Curr Gene Ther ):469-85; PubMed ID:()
38&& Lee TK, Man K, Ho JW, Wang HX, Poon RT, Sun KW, Ng KT, Ng IO, Xu RA, Fan ST. The significance of RAC-signaling pathway in HCC cell motility: Implication for a new therapeutic target. Carcinogenesis ):681-7PubMed ID:()
39&& Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu RA, Fan ST. FTY 720 induce apoptosis of human hepatoma cell lines through PI3-K mediated Akt dephosphorylation. Carcinogenesis ) . PubMed ID:( )
40&& Ma H, Liu YX, Liu SL, Xu RA, Zheng DX. Expression of TRAIL (114-281) mediated by adeno-associated virus and its tumoricidal activity. Zhonghua Yi Xue Za Zhi ):1635-41. PubMed ID:()
41& Tu SP, Cui JT, Liston P, Jiang XH, Xu RA, Lin MCM, Zhu YB, Zou B, Samuel SM Ng, Xia HX, Wong WM, Chan OO, Yuen MF, Lam SK, Kung HF, Wong BCY. Gene therapy for colon cancer by adeno-associated virus-mediated transfer of surviving Cys84Ala mutant. Gastroenterology
(2): 361-75. PubMed ID:( )
42& Sun X, Krissansen GW, Fung PWC, Xu S, Shi J, Man K, Fan ST, Xu RA*. Anti-angiogenic therapy subsequent to adno-associated virus mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int J Cancer
(4) 670-7. PubMed ID:()
43& Tsui TY, Lau CK, Ma J, Wu X, Wang YQ, Farkas S, Xu R, Schlitt HJ, Fan ST. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: A new approach to attenuate liver fibrosis in rats. Hepatology
PubMed ID:( )
44& Sun X, Qiao H, Jiang H, Zhi X, Liu F, Wang J, Liu M, Dong D, Kanwar JR, Xu R, Krissansen GW. Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors. ancer Gene Ther. ):35-45. PubMed ID:()
45& Xu RA*, Sun X, Tse LY, Li H, Chan PC, Xu S, Xiao W, Kung HF, Krissansen GW, Fan ST. Long-term expression of angiostatin and suppression of liver metastatic cancer. Hepatology 1-61. PubMed ID:()
46& Li XY, Xu RA, Wang GJ, Xie HT, Zhao XC, Chen M. Effects of rAAV/rSTAP on mRNA Lever of interstitial collagenase in rat stellate cell. Chin J Clin Pharmacol Ther ):1236-8.
47& Cai KX, Sham MH, Zheng DX, Xu RA*. Anti-HBV medicine and treatment. Chinese Journal of Internal Medicine -6.
48& Chen Y, Luk KDK, Cheung KMC, Xu RA*, Lin M, Lu WW, Leong JCY, Kung HF. Gene therapy for new bone formation using an adeno-associated viral bone morphogentic protein-2. Gene Therapy 5-53. PubMed ID:()
49& Xu RA*, Cai KX, Zheng D, Ma H, Xu S, Fan ST. Molecular therapeutics of HBV. Curr Gene Ther ): 341-55. PubMed ID:( )
50& Shi J, Zheng DX, Man K, Fan ST, XU RA*. TRAIL: A potential agent for cancer therapy. Curr Mol Med 7-736. PubMed ID:( )
51& Ma H, Xu RA, Cheng H, Kuo HS, During MJ, Fang RH. Gene transfer into human keloid tissue with adeno-associated virus vector. J Trauma ): 569-573. PubMed ID:()
52& Cai, KX, Sham MH, Tam P, Lam WK, Xu RA*. Lung cancer gene therapy. Gene Ther Mol Biol -72.
53& Xu RA*, Li H, Tse L, Kung HF, Lu H, Lam KSL. Diabetes gene therapy: potential and challenges. Curr Gene Ther ):65-83. PubMed ID:( )
54& Diao Y, Xu RA, Wang GJ, Zhao XC. Adeno-associated virus mediated expression of human erythropoietin in vitro. Acta Pharmacol Sin ): 55-58. PubMed ID:(1186073 )
55& Jung SC, Han IP, Limaye A, Xu RA, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P. Adeno-associated viral vector-mediated gene transfer results in log-term enzymatic and functional correction in multiple organs of fabric mice. Proc Natl Acad Sci USA 76-81. PubMed ID:( ) (IF 10.5)
56& Mastakov M, Baer C, Xu RA, Fitzsimons H, During MJ. Combined injection of AAV with manitol into rat brain. Mol Ther 5- 32. PubMed ID:()&
57& Xu RA, Janson CG, Mastakov M, Lawlor P, Young D, Mouravlev A, Fitzsimons J, Choi KL, Ma H, Dragunow M, Leone P, Chen Q, Dicker B and During MJ. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther 3-32. PubMed ID:()
58& During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons H, Poulsen D, Leone P, Xu RA, et al An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science : 1453-60. PubMed ID:()& (IF 29.6)
59& Dragunow M, Xu R, Walton M, Woodgate A, Lawlor P, MacGibbon GA, Young D, Gibbons H, Lipski J, Muravlev A, Pearson A, During M. c-Jun promotes neurite outgrowth and survival in PC12 cells. Mol Brain Res -2): 20-33. PubMed ID:()
60& Walton M, Woodgate A, Muravlev A, Xu R, During M, Dragunow M. CREB phosphorylation promotes nerve cell survival. Journal of neurochemistry 73 (5) , 99) PubMed ID:( )
61& During MJ, Xu RA, Young D, Kaplitt M, Sherwin R, Leone P Peroral gene therapy of lactose in tolerance using an adeno-associated virus vector. Nat Med 31-6. PubMed ID:(9771745)
62& Wang Q，Lv Y, Xu RA*. Dose-response and control of adeno-associated viral vectors based preclinical and clinical gene therapy. Chinese Journal of Clinical Pharmacology and Therapeutics. 2-1194.
63& Lv Y, Q, Wang, Y Diao, RA Xu* Optimization of the Transfection Efficiency of Human Hepatic Stellate Cell and Hepatocyte Using Liposome. Journal of HuaqiaoUniversity (Natural Science). ): 49-52.
64& Wang Q, Lv Y, Xiao W, Diao Y, Xu R*. The clinical researches of recombinant adeno-associated vectorr. China biotechnology, ):73-79
65& Wang Q, Diao Y, Lv Y, Li Z, Xu R. Mutant K-ras-specific siRNA inhibits proliferation, migration and induces apoptosis of lung cancer A549 cells. Chin J Cancer Biotherapy, ):564-9.
66& Diao Y, Wang Q, Lv Y, Xu R. Hurdles and solutions to noninvasive pulmonary delivery gene medicine. Chinese Journal of New Drugs and Clinical Remedies, 1-575
67& Huang X, Wang X, Dong H, Zhao X, Li Z, Wang Q, Xu R, Diao Y. High level expression of recombinant human kallistatin in Pichia pastoris and its bioactivity. Chin J Biotech, ):249~255
68& XU RA* Exploring oral delivery of medical nanoparticle and gene medicine& Chinese Journal of Clinical Pharmacology and Therapeutics& 92-1097.54.
69& Wang F, Diao Y, Xu RA*&&& Large scale production of adeno-associated viral vectors for clinical trials& China biotechnology&&& 2010
70& Diao Y, Xu R& Oral devivery of adeno-associated viral vectors& Yao Xue Xue Bao. ):703-9.& PubMed ID:( )
71& 吴龙火, 许瑞安*. 九里香中香豆素Paniculal的化学合成途径. 海峡药学, ):168-169.
72& 王启钊, 吕颖慧，李招发，刁勇，许瑞安*. 腺相关病毒的衣壳装配和DNA衣壳化机制 生物工程学报 in press.
73& 王启钊，李招发，江楠，刁勇，许瑞安*. 铁过载氧化应激模型的构建、检测与分析. 中国临床药理学与治疗学. In press.
74& 龚玉华, 王启钊, 许瑞安*. 非组蛋白HMGA2: 抗肿瘤药物的新靶标．中国药物杂志. 2010 N 45(2):.
75& 王启钊, 吕颖慧, 肖卫东, 刁　勇, 许瑞安*. 重组腺相关病毒载体临床实验研究. 中国生物工程杂志, ): 73-79.
76& 卢　超, 王启钊, 许瑞安*. 重组腺相关病毒载体的整合性研究进展 生命科学, ): 459-465.
77& 卢超, 万江波, 唐明清, 肖卫东, 许瑞安*. 重组腺相关病毒载体的免疫性研究及其解决策略. 中国临床药理学与治疗学, 2010 M 15 (5): 577-583.
78& 刁　勇*，许瑞安. 重组腺相关病毒基因药物的细胞免疫毒性及对策. 药学学报. ): .
79& 黄晓平, 王　晓, 董　浩, 赵小峰, 李招发, 王启钊, 许瑞安, 刁　勇*. 重组人可溶性TRAIL 在毕赤酵母中表达与纯化及其抗肿瘤细胞活性. 中国生化药物杂志. ):73-77.
80& 黄晓平，王晓，董浩，赵小峰，李招发，王启钊，许瑞安，刁勇*.& 重组人kallistatin 蛋白在毕赤酵母中的高效表达及生物活性分析. 生物工程学报. 2010 F 26(2): 249 - 255.
81& 吕颖慧，王启钊，刁勇，许瑞安*. 脂质体转染人肝星状细胞和肝细胞条件优化. 华侨大学学报(自然科学版), 2010, J 31(1): 49-52.
82& 梁丽英，张国海，许瑞安*. 脂肪酸合成酶抑制剂研究热点及其开发.中国现代应用药学. 2010 A 27(4): 300-303.
83& 熊亚楠, 李招发, 许瑞安*. 纤溶酶系统与阿尔茨海默症. 生命的化学. ):76-80.
84& 王启钊, 吕颖慧, 江　楠, 刁　勇, 许瑞安*. 干细胞不均匀分裂与肿瘤发生. 癌症. ): 265-271.
85& 刘建福, 范燕萍, 许瑞安*. 福建泉州地区珍稀野生药用植物资源与保护. 热带作物学报. 2010 F 31 (2): 284-291.
86& ZHAO Yong-Gang, LI Hua, XU William2, LUO Jia, XU Rui-An*. An Overview of the Fibrinolytic Enzyme from Earth-worm. 中国天然药物. 2010 J 8(4): 301-308.
87& 施伟杰, 毕丽伟, 许瑞安*. 联合细胞穿膜肽的肿瘤靶向载体. 中国肿瘤生物治疗杂志. 2010 F 17(1): 104-114.
88& 李　培, 邱　飞, 吴龙火, 许瑞安. 多功能信封式纳米载体研究进展. 中国生物工程杂志. ): 139-143.
89& 吴龙火, 许瑞安*. 简单香豆素药理作用与构效关系研究进展. 医药导报. 2010 A 29(14): 498-501.
90& 毕丽伟, 施伟杰, 许瑞安*. 细胞衰老与慢性肝病及对肝纤维化的调节作用. 江苏预防医学. 2010 M 21(12):67-69.
91& 唐明青, 王启钊, 许瑞安*. 癌基因成瘾-肿瘤分子靶向药物研发的一种新思路. 中国肿瘤生物治疗杂志. 2010 A 17(2): 213-220.
92& 曾庆友, 许瑞安. 阿魏酸乙酯的一锅法合成. 中国医药工业杂志. ): 255-256.
93& 张国海, 梁丽英, 许瑞安*. RNA干扰抗丙型肝炎病毒的研究进展. 重庆医学, 2010 J 39(14): .
94& 张国海, 王启钊, 张景红, 许瑞安*. microRNA调控的靶向性病毒载体在基因治疗中的应用. 生物工程学报. 2010 J 26(6): 707-714.
95& 王启钊, 刁勇, 吕颖慧, 李招发, 许瑞安*. 突变型K-ras siRNA对肺癌细胞的影响. 中国肿瘤生物治疗杂志. 2009, Accepted.
96& 王峰、刁勇、许瑞安* 重组腺相关病毒规模化生物包装技术. 生物工程学报2009, November 25; 25(11):
97& 王启钊, 吕颖慧, 许瑞安* 肿瘤基因治疗的一点思路. 中国肿瘤临床, 2009, Accepted.
98& 罗海涛 许瑞安& 肿瘤干细胞研发热点&& 生命科学， 中国上海&& 2009& Accepted.
99& 张亭亭，李招发，许瑞安*& 重组可溶性细胞球蛋白的制备、纯化与抗氧化活性检测. 华侨大学学报，2009
100& 徐韬, 许瑞安*不同作用途径抗肿瘤中药的筛选与前瞻. 华侨大学学报, 2009， 108（33）， 359-365
101& 吕颖慧，王启钊，肖卫东, 刁勇，许瑞安*. 自身互补型腺相关病毒载体研究进展.生物工程学报, ):658~66.
102& 刁勇, 许瑞安&& 口服重组腺相关病毒基因药物.药学学报, ): 703-709.
103& 吴龙火; 王晓; 许瑞安*& 九里香叶总黄酮提取工艺的研究. 广西轻工业, -4.
104& 唐明青; 刁勇; 许瑞安* 以壳聚糖为载体的口服基因药物. 中国生化药物杂志, ):139-140.
105& 王峰; 刁勇; 许瑞安* 重组腺相关病毒载体在肺癌治疗中的应用. 海峡药学, ):8-11.
106& 张红; 曾庆友; 林建明; 许瑞安* 白藜芦醇化学合成研究进. 精细化工中间体, ):7-11.
107& 曾庆友，曾明荣, 许瑞安* 对氧甲基肉桂酸乙酯一锅式绿色合成法& 精细化工 )：192-4.
108& Wang Q，Lv Y, Xu RA*. Dose-response and control of adeno-associated viral vectors based preclinical and clinical gene therapy. Chinese Journal of Clinical Pharmacology and Therapeutics. 2-1194.
109& 舒静波，刁勇，许瑞安* 腺病毒-腺相关病毒嵌合纳米载体研究进展.华大学报 ):172-176.
110& 曾庆友，张红，许瑞安, 3，4-二甲氧基肉桂酸乙酯的一锅式合成. 青岛科技大学学报, 2008,(6)
111& 李华; 陈陵霞; 许瑞安* 纤溶活性的药学测定方法研究. 中国临床药理学与治疗学. ):
112& 曾庆友，曾明荣, 许瑞安* 对氧甲基肉桂酸甲酯一锅式绿色合成法.精细化工, )：192-194.
113& 曾庆友; 张红; 许瑞安; 3,4-二甲氧基肉桂酸乙酯的一锅式合成. 青岛科技大学学报, ):490-492.
114& 刁勇，局海亮, 许瑞安. 单环刺螠抗血栓组分的分离纯化和药效学研究. 中国生化药物学杂志, 9-200.
115& 吴龙火, 许瑞安.小胶质细胞及P38、MAPK 在圣经病理性疼痛中的作用. 科学研究, 38（2）:16-18, 2008.
116& 许瑞安. 医用纳米与基因药物口服化的探索.中国药理学与药物治疗学. 92-1097.54.
117& 曾庆友; 曾明荣; 许瑞安; 对甲氧基肉桂酸甲酯的一锅式绿色合成. 化学合成， ):663-664.
118& 史娟, 刘彦信, 刘士廉, 许瑞安, 郑德先. 腺相关病毒介导Smac和DR5单链抗体表达对抑制肿瘤细胞生长的作用；中华医学杂志 ):1857-9. (SCI)
119& 许瑞安*, 刁勇, 谢海棠. 基因药物在临床上的最新应用与研发.中国药理学与药物治疗学 92-7.
120& 王佃亮; 刘万顺; 韩宝芹; 许瑞安; 张海智; 刘学英. 一种新型海洋纤溶酶体外抗凝与溶栓作用研究. 中国海洋药物, ): 37-41
4. ABSTRACTS FOR INTERNATIONAL CONFERENCES AND GUEST SPEAERS：(11.1, total﹥50，partially list as below)
1& 许瑞安&& Cytoglubin抗肝纤维化的机理及其在临床应用前景& 中国科学院广州生物健康研究院专题讲座 （特邀嘉宾）2008年 4月20日
2& 许瑞安* 口服基因治疗&& 天津滨海高科技园 (邀请报告) 日
3& 许瑞安*& Function of Cytoglubin on anti-aging and application on skin protection. The Anit-aging Symposium Annual Meeing , June 29, 2008 （Invited speaker）台北，台湾
4& RA Xu*&& Double stranded microRNAs, a kind of potential anti-cancer agents, act similarly to siRNAs but with multi-targets BIT& 3rd World Cancer Congress 2010& Singapore （Invited speaker）
5& RA Xu*, W Shi&&& The recombinant Tat-CYGB protein, an anti-cancer agent for liver dease.& AGST. 2010, May 15-19, Seattle, USA
6& Lu C, Wang Q, RA Xu& Double-stranded Let-7 Mimics, a Kind of Potential Anti-cancer Agents& AGST. 2010, May 15-19, Seattle, USA
7& 曾庆友 张红，许瑞安&&& 固体光气法合成3，4，5-三甲氧基苯甲酸酐，全国第15届有机和精细化工中间体学术交流会 -14 天津
8& Xu, RA*.& Potential and Challenges of Diabetes gnene therapy&& BIT’S 1st Annual World Congress of Endobolism-2011, Xiamen, China ()
9& J.Shi, Y Liu, Y Guo, J Zhang, X Li, P-t Cheung, F Farzaneh, DX Zheng, RA Xu*.& Expression of an Anti-DR5 Single Chain Antibody in Muscles of Nude Mice Prevents Cancer Growth. The 2nd International Cancer Meeting, Hong Kong, 2006
10& 王峰 许瑞安&& rAAV制备技术&& 福建省 2010年药理学年福州, 2010年 12月 22 日
11& XU RA*. Anti-angiogenic inhibitors on cancer gene therapy. ISCGT. 2005,& December 9-11, Shenzhen, China
12& XU, RA*, Rahimi M, Ma H, Fung P, Farzaneh F, During MJ. Stability of infectious recombinant adeno-associated viral vector in gene delivery. ISCGT. 2005,& December 9-11, Shenzhen, China
13& Tse L-Y. Xu RA*.& Suppression of Hepatocellular carcinoma growth by kallistatin and vasostatin. ISCGT. 2005, December 9-11, Shenzhen, China
14& Liu Y, Guo Y, Tao X, Chn C, Liu S, XU RA*, Zheng DX. A novel anti- human DR5 monoclonical antibody with tumor –therapeutic potential.&&& ISCGT. 2005, December 9-11, Shenzhen, China
15& Shi J, Zheng DX, Liu Y, Farzaneh F, Sham MH, XU RA*. TRAIL gene therapy of lung cancer. ISCGT. 2005, December 9-11, Shenzhen, China
16& Cai KX, Sham MH, Xiao W, Tam P, XU RA*. Angiogenic inhibitors suppresses lung cancer growth in spontaneous pulmonary metastasis mouse model. ISCGT. 2005, December 9-11, Shenzhen, China
17& Sun X, XU RA*, Farzaneh F, Krissensan GW. Over-expression of on Hippel-Lindau tumor suppressor protein and antisense HIF-1& eradicates gliomas.&&&& ISCGT. 2005, December 9-11, Shenzhen, China
18& Xu RA, PM Harrison, P-T Cheung, S Xu, F Farzaneh. Expression of cytoglobin inhibits hepatic stellate cell activation and liver fibrosis in toxic and cholestatic models of liver injury. The 41th ESLS Annual Meeting. 2006,&&& Vienna, Austria
19& Xu RA*, Tse L-Y. Suppression of HCC growth by angiogenic inhibitors. The 41th ESLS Annual Meeting. 2006. Vienna, Austria
20& Dai J, Rabie AB, Xu RA. AAV mediated VEGF gene therapy to control mandibular condylar growth. 20th IADR-SEA travel award poster presentation. 2006, Malacca, Malaysia
21& Dai J, Rabie AB, Xu RA. Transduction characteristics of rAAV hybrids in chondrocytes and osteoblasts. IADR/Unilever Hatton Award competition Brisbane, 2006, February 22, Australia
22& Xu RA*. Anti-angiogenic agents for cancer therapy. The 4th Congress of International Drug Science and Technology. 2006, May 26- Jun 1, Dalian, China
23& Xu RA*, PM Harrison, M Chen, X Li, PT Cheung, W Xiao, F Farzaneh. Inhibition of hepatic stellate cell activation and liver fibrosis by expression of Cytoglobin in vivo. The 9th American Society of Gene Therapy Meeting. 2006, May 31-June 4. Baltimore, USA
24& Xu RA*, J Ma, Peter CW Fung, KW Chu, N Habib, F Farzaneh. Two new anti-angiogenic inhibitors for treatment of colon cancer. ISCGT. 2006, Japan
25& Xu, RA*, Kexia Cai, Paul Tam, Qizhao Wang, Mai Har Sham&&& Suppression of Lung Tumor Metastasis in Mice by Recombinant Adeno-Associated Virus- mediated Expression of Vasostatin. ISCGT 2007, Nov 18-20. India. (Invited speaker)
26& RA Xu, X Li, Y Diao, P Harrison, W Xiao, N Habib, F Farzaneh.&&& Long-term effect and biosafety of rAAV-rat Cygb expression AGST. 2007 June 1, Seattle, USA
27& Xu, RA, Qizhao Wang, Yinghui Lv.&&&&&&&&&&& Dose-Response and Control in Viral Vectors Based Preclinical and Clinical Therapy. International Quantitative Pharmacology Conference 2007, October28-31, Nanijng, China (Invited speaker)
28& Xu, RA, Qizhao Wang, Yinghui Lv.&&&&&&& miRNA in lung cancer. International Society for cell and gene therapy of Cancer (ISCGT) conference, 2008, Sep., Shijiazhuang,China (Invited speaker)（第五届中国肿瘤学术大会）
29& Qizhao Wang, Xu, RA&&&& microRNA in lung cancer. 第四届南北肺癌高峰论坛,-20. 广州,中国.&&&&&&
30& 王晓; 许瑞安. 第二届中草药提取关键技术与提取物产业应用研讨会. 厦门 2009
31& 王启钊、吕颖慧、许瑞安&&&&& 肿瘤基因治疗的思路与出路. 肿瘤病因学研究与中西医结合肿瘤综合整流交流研讨会论文集. -9., 厦门.
32& Mingqing Tang, Qizhao Wang, Ruian Xu.&&&& DNMTs and its related epigenetic regulation in lung tumorigenesis. 肿瘤病因学研究与中西医结合肿瘤综合整流交流研讨会论文集. -9. 厦门
33& 许瑞安.&& Cytoglubin抗肝纤维化机理 (特邀嘉宾), 福建省 2008年药理学年福州,2008年 12月 16 日
34& 许瑞安&&& 生命科学的活力与分子药物学的张力& (特邀嘉宾) 泉州市药学年会讲 座, 2008年& 11月& 3日
35& Wang QZ, Habib N, Xiao W, Xu RA.&&&&& Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy AGST 2009 May 30- June 2 , Boston,& USA
36& Tang M, Wang Q, Xiao W., Xu RA*&&&&&&&& DNMTs and its related epigenetic regulation in lung tumorigenesis& AGST. 2009 May 27-30 , Santiago, USA
37& Zhang Tingting, Li Z, Meng C, Xu RA*& Mechanism of Anti-aging and Trends in Applications of Skin Anti-aging Pharmaceuticals 第十二届全国数学药理学术大会, 西宁, 8-10, 8,2009 (邀请嘉宾)
38& 吴龙火、许瑞安& 九里香中香豆素paniculal 的化学合成途径& 2009 年全国药物化学学术会议 2009.10& 武汉 中国
39& Xu RA*.& Reducing de novo capsid synthesis from replication competent AAV contamination in the targeting tissue& IT Life Sciences’3rd Annual World Congress of Gene 2009& (invited speaker)
OTHER ACEDMIC ACTIVITIES:
1.&&& Council Excutive Member of International Society of Cell & Cancer Gene Therapy
2.&&& Member of Editorial Board of Islet& (Swenden)；
3.&&& International Panel of Medical Science Monitor （USA）；
4.&&& Member of Editorial Board of World Journal of Gastroenterology Pharmacology and Treatment；
5.&&& Member of Editorial Board of World Journal of Hepatology；
6.&&& Member of Editorial Board of World Journal of Clinical Oncology；
7.&&& Reviewer of Hepatology （USA）；
8.&&& Reviewer of Gene Therapy (USA)；
9.&&& Reviewer of Journal of Applied Polymer Sciences；
10.&& Reviewer of International Journal of Cancer (Germany)；
11.&& Reviewer of Apoptosis (USA)；
12.&& Reviewer of Applied Biochemistry and Biotechnology (USA)；
13.&& Reviewer of Journal of Pharmacy and Pharmacology (UK)；
14.&& Reviewer of Jounral Biomedical Science；
15.&& Reviewer of Tumor Biology (Swenden)；
16.&& Reviewer of JPP (USA)
17.&& Reviewer of Journal of Cellular Physiology (USA)
18.&& Reviewer of Cancer Immunology Immunotherapy
19.&& Reviewer of Cancer Letter
20.&& Reviewer of Irish National Health Research Grant
21.&& Scientific Committee member of 2006 Cancer Gene Therapy, Japan.
22.&& Chairman of 2nd International Conference of Clinical Quantitative Pharmacology and New Drug Evaluation, October 29-31, 2010.
23.&& BIT’S 1st Annual World Congress of Endobolism-2011 (大会主持人)
24.&& 丰泽区政府社会经济顾问；
25.&& 晋江市人民政府顾问团顾问；
26.&& 泉州（永春）生物医药产业顾问团顾问；
27.&& 泉州市抗癌协会顾问；
28.&& 泉州市中药现代化工程中心主任；
29.&& 泉州医药同业会高级顾问；
30.&& 泉州市人民政府技术创新工程专家顾问；
31.&& 厦门市科技局评审专家；
32.&& 福建省药物化学重点实验室副主任；
33.&& 安徽省临床药物评价中心顾问；
34.&& 《中国临床药理学和治疗学》编委、顾问；
35.&& 《中国海洋资源》特邀编委；
36.&& 科技部科技发展战略专家；
37.&& 科技部国际合作管理专家；
38.&& 科技部企业技术专家；
39.&& 国家自然科学基金网上评审专家。
版权所有&华侨大学生物医学学院}